trending Market Intelligence /marketintelligence/en/news-insights/trending/GDBP_34dywBfOKrrxO-hgw2 content esgSubNav
In This List

Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Sunovion Pharmaceuticals Inc. and Novartis AG signed an exclusive license agreement for U.S. commercialization rights to three approved chronic obstructive pulmonary disease drugs.

Under the deal, Sunovion will hold exclusive commercialization rights to Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler in the U.S. Novartis will continue to manufacture the three drugs.

The U.S. FDA approved Utibron Neohaler and Seebri Neohaler in 2015. Sunovion plans to bring these two drugs to market in 2017. Arcapta Neohaler was approved in the U.S. in 2011 and arrived in the market in 2012.

Sunovion Pharmaceuticals is a unit of Sumitomo Dainippon Pharma Co. Ltd.